Program
rosuvastatin
Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 705 open or running | phase 4since Oct 7, 2005 | Sep 16, 2005 | Jan 25, 2027phase 1 · NCT07534592 |
| Yuhan | 100 open or running | phase 4since Jul 12, 2017 | Jan 5, 2012 | none ahead |
| Chong Kun Dang Pharmaceutical | 80 open or running | phase 2since Nov 27, 2016 | Jan 24, 2014 | none ahead |
| Organon | 60 open or running | phase 4since Mar 31, 2008 | Aug 25, 2004 | none ahead |
| GlaxoSmithKline | 40 open or running | phase 1since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Merck | 41 open or running | phase 3since Oct 10, 2025 | Jun 17, 2015 | none ahead |
| Hanlim Pharm. | 30 open or running | phase 3since Jun 17, 2018 | Jun 17, 2018 | none ahead |
| IlDong Pharmaceutical | 30 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceutical | 30 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| Lotus Pharmaceutical | 30 open or running | phase 3since May 13, 2015 | Mar 4, 2014 | none ahead |
| Celltrion | 20 open or running | phase 3since Apr 27, 2026 | Jul 30, 2021 | none ahead |
| Daewon Pharmaceutical | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Daewoong Pharmaceutical | 20 open or running | phase 3since Nov 7, 2019 | Mar 14, 2014 | none ahead |
| Daiichi Sankyo | 20 open or running | phase 1since Sep 11, 2025 | Sep 11, 2025 | none ahead |
| Hanmi Pharmaceutical | 20 open or running | phase 1since Mar 9, 2014 | Mar 9, 2014 | none ahead |
| kobe-university | 20 open or running | phase 4since Jun 15, 2017 | Jun 15, 2017 | none ahead |
| LG Chem | 20 open or running | phase 3since Aug 5, 2013 | Aug 5, 2013 | none ahead |
| Ache Laboratorios Farmaceuticos | 10 open or running | phase 3since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| d16-pharma-biotec-ltd | 10 open or running | phase 4since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Dong-A ST | 10 open or running | phase 4since Oct 29, 2014 | Oct 29, 2014 | none ahead |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | none ahead |
| HK inno.N | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharm | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Jiangsu HengRui Medicine | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| NVP Healthcare | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| pin-siang-medical-biotechnology-co-ltd | 10 open or running | no phasesince Nov 6, 2013 | Nov 6, 2013 | none ahead |
| verisfield-uk-ltd-greek-branch | 10 open or running | phase 1since May 9, 2016 | May 9, 2016 | none ahead |
Also a collaborator on its studies: parexel, pharma-medica-research-inc, Pfizer, Regeneron Pharmaceuticals, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene, Eli Lilly, linical-korea and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Oct 29, 2014.
- Dec 2, 2024Phase 3 study in DyslipidemiasAstraZeneca · NCT06834932 · 432 enrolled · China, Hong Kong
- Dec 16, 2024Phase 1 study in DyslipidemiasAstraZeneca · NCT06742853 · 81 enrolled · United States, United Kingdom
- May 23, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in DyslipidemiasNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07001787 · 88 planned
- Jul 17, 2025Phase 1 study in Healthy ParticipantsAstraZeneca · NCT07088913 · 20 enrolled · United States
- Sep 11, 2025Daiichi Sankyo's first studies: 2 phase 1 studies in Healthy SubjectsNew to Daiichi SankyoDaiichi Sankyo · NCT07182383, NCT07201545
- Oct 10, 2025Phase 3 study in HyperlipidemiasMerck · NCT07216482 · 996 enrolled · United States, Argentina, Australia and more
- Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
- Dec 10, 2025Phase 1 study in HealthyMerck · NCT07300280 · 60 enrolled · United States
- Dec 19, 2025Phase 1 study in HyperlipidemiasAstraZeneca · NCT07316608 · 44 enrolled · United States
- Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592 · 48 enrolled · United States
- Apr 27, 2026Phase 3 study in HypertensionPhase 3 reachedCelltrion · NCT07564726 · 163 enrolled · South Korea
- May 26, 20262 phase 3 studies in HypercholesterolemiaAstraZeneca · NCT07619131, NCT07619118
- Nov 5, 2026Phase 3 study in HypercholesterolemiaAstraZeneca · NCT07930507 · 204 planned · China, Hong Kong, Malaysia and more
- Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592
Ahead
- Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592
- Feb 22, 2027Primary completion: phase 3 study in DyslipidemiasAstraZeneca · NCT06834932
- May 28, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619118
- Jul 30, 2027Primary completion: phase 3 study in HypercholesterolemiaAstraZeneca · NCT07619131
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 138 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07930507Hypercholesterolemia · China, Hong Kong, Malaysia and more | 3 | Not yet recruiting | AstraZeneca | Oct 11, 2027 | 204 |
| NCT07619131Hypercholesterolemia · United States, Bulgaria, Canada and more | 3 | Recruiting | AstraZeneca | Jul 30, 2027 | 600 |
| NCT07619118Hypercholesterolemia · United States, Australia, Canada and more | 3 | Recruiting | AstraZeneca | May 28, 2027 | 200 |
| NCT07564726Hypertension · South Korea | 3 | Completed | Celltrion | Feb 13, 2024 | 163 |
| NCT07534592Diabetes Mellitus, Type 2 · United States | 1 | Active, not recruiting | AstraZeneca | Jan 25, 2027 | 48 |
| NCT07316608Hyperlipidemias · United States | 1 | Completed | AstraZeneca | Jun 5, 2026 | 44 |
| NCT07300280Healthy · United States | 1 | Completed | Merck | Oct 14, 2026 | 60 |
| NCT07222098Healthy · United States | 1 | Completed | Merck | Dec 14, 2025 | 16 |
| NCT07216482Hyperlipidemias · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Aug 3, 2026 | 996 |
| NCT07201545Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Dec 10, 2025 | 58 |
| NCT07182383Healthy Subjects · Portugal | 1 | Completed | Daiichi Sankyo | Nov 24, 2025 | 58 |
| NCT07088913Healthy Participants · United States | 1 | Completed | AstraZeneca | Feb 20, 2026 | 20 |
| NCT07001787Dyslipidemias | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Feb 2026 | 88 |
| NCT06742853Dyslipidemias · United States, United Kingdom | 1 | Completed | AstraZeneca | Oct 29, 2025 | 81 |
| NCT06834932Dyslipidemias · China, Hong Kong | 3 | Active, not recruiting | AstraZeneca | Feb 22, 2027 | 432 |
| NCT06646354Hypertension · Korea, Republic of | 3 | By invitation | hyundai-pharm | May 19, 2025 | 125 |
| NCT06554821Healthy Participants · Germany | 1 | Completed | AstraZeneca | Oct 8, 2024 | 28 |
| NCT06475872Primary Hypercholesterolemia · Korea, Republic of | 1 | Completed | Hanlim Pharm. | Dec 7, 2023 | 36 |
| NCT06160414Healthy · United Kingdom | 1 | Completed | AstraZeneca | Feb 5, 2024 | 20 |
| NCT06112678Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Feb 19, 2024 | 63 |
| NCT05768360Healthy Male Subjects · Germany | 1 | Completed | AstraZeneca | Jun 24, 2023 | 6 |
| NCT05749861Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jun 7, 2023 | 65 |
| NCT05549401Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Nov 30, 2022 | 32 |
| NCT05384262Dyslipidemias · United States, United Kingdom | 1 | Completed | AstraZeneca | Jun 14, 2024 | 183 |
| NCT05192356Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 8, 2022 | 63 |
| NCT05002244Health, Subjective · Korea, Republic of | 1 | Completed | Celltrion | Aug 29, 2021 | 37 |
| NCT04883658Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 20, 2021 | 62 |
| NCT04659070Hypertension · Korea, Republic of | 3 | UNKNOWN | Hanlim Pharm. | May 19, 2022 | 156 |
| NCT04428086Solid Tumor, Adult · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 19 |
| NCT04258865Hypertension · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 26, 2020 | 30 |
| NCT04161001Hypertension · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Nov 20, 2021 | 237 |
| NCT04158076Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Jan 14, 2021 | 131 |
| NCT04056169Acute Coronary Syndrome · Korea, Republic of | 4 | Completed | Yuhan | Jul 23, 2019 | 50 |
| NCT03872232Hypercholesterolemia · Korea, Republic of | 3 | Completed | Yuhan | Aug 12, 2020 | 180 |
| NCT03847506Hypertension · Korea, Republic of | 4 | Completed | HK inno.N | Dec 2, 2020 | 127 |
| NCT03657758Coronary Artery Disease · Japan | 4 | UNKNOWN | kobe-university | Aug 31, 2020 | 75 |
| NCT03571087Primary Hypercholesterolemia | 3 | Completed | Hanlim Pharm. | Aug 2015 | 374 |
| NCT03566316Hypertension With Hyperlipidemia · Korea, Republic of | 3 | Completed | IlDong Pharmaceutical | Jun 16, 2017 | 134 |
| NCT03550859Renal Insufficiency, Chronic · Korea, Republic of | 4 | UNKNOWN | Yuhan | Dec 2021 | 374 |
| NCT03217409Diabetes Mellitus · Korea, Republic of | 4 | Completed | Yuhan | Apr 3, 2019 | 85 |
| NCT03192579Coronary Artery Disease Progression | 4 | Completed | kobe-university | Jun 2, 2017 | 50 |
| NCT03019549Healthy · United States | 1 | Completed | AstraZeneca | May 22, 2017 | 42 |
| NCT02977065Dyslipidemias · Australia | 2 | Completed | Chong Kun Dang Pharmaceutical | Dec 30, 2017 | 62 |
| NCT02963116High Risk Coronary Artery Disease · United Kingdom | 1 | Completed | AstraZeneca | Mar 1, 2017 | 12 |
| NCT03210532Hypertension · Korea, Republic of | 3 | Completed | Daewon Pharmaceutical | Sep 2017 | 129 |
| NCT02933658Hypertension | 1 | Completed | Daewon Pharmaceutical | Nov 2015 | 71 |
| NCT02951962Hypertension · Korea, Republic of | 1 | Completed | Yuhan | Sep 2016 | 60 |
| NCT02859129Hypertriglyceridemia · United States | 1 | Completed | AstraZeneca | Nov 2013 | 114 |
| NCT02827903Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Jeil Pharmaceutical | Nov 21, 2017 | 237 |
| NCT02767310Healthy · India | 1 | Completed | verisfield-uk-ltd-greek-branch | Jun 2016 | 49 |
| NCT02748057Hypercholesterolemia | 3 | Completed | Organon | Dec 11, 2017 | 135 |
| NCT02741245Hypercholesterolemia | 3 | Completed | Organon | Jan 18, 2017 | 321 |
| NCT02707224Healthy | 1 | Completed | Lotus Pharmaceutical | Jun 2015 | 40 |
| NCT02546323Atherosclerosis · China | 3 | Completed | AstraZeneca | Jan 29, 2019 | 543 |
| NCT02477514Skin Diseases, Bacterial | 1 | Completed | Merck | Aug 2015 | 18 |
| NCT02445352Primary Hypercholesterolemia · Korea, Republic of | 3 | Completed | Lotus Pharmaceutical | Jan 2015 | 379 |
| NCT02434497Homozygous Familial Hypercholesterolemia · Belgium, Canada, Denmark and more | 3 | Completed | AstraZeneca | Nov 17, 2016 | 9 |
| NCT02387619Hypertension · Korea, Republic of | 1 | Completed | Jeil Pharmaceutical | Mar 2015 | 41 |
| NCT02289430Healthy | 1 | Completed | NVP Healthcare | Feb 2015 | 59 |
| NCT02280590Hyperlipidemias · Korea, Republic of | 4 | Completed | Dong-A ST | Jun 2015 | 223 |
How it is read
Names in the registry
- “Rosuvastatin”, 105 entries
- “rosuvastatin”, 10 entries
- “CKD-828, D097, D337”, 6 entries
- “Rosuvastatin 20mg”, 6 entries
- “Ezetimibe/Rosuvastatin”, 4 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 43 studies
- Hypertension, 23 studies
- Dyslipidemias, 9 studies
- Hyperlipidemias, 6 studies
- Coronary Artery Disease, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.